Nvidia Options Price in $280 Billion Earnings Swing 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
Tesla Raises Cybertruck Prices by $5,000 in US 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 
Add as a preferred source on Google
Eli Lilly (NYSE: LLY) is reportedly in advanced discussions to acquire psychedelic drug developer AtaiBeckley, a move that could significantly strengthen the pharmaceutical giant’s neuroscience portfolio. According to a Bloomberg News report citing people familiar with the matter, the deal could be announced as early as this week.
The Indianapolis-based drugmaker is said to be negotiating an acquisition at a premium to AtaiBeckley’s current market value, which has reached approximately $2 billion after the biotech company’s shares surged more than 100% over the past year.
The potential transaction reflects Lilly’s growing interest in psychedelic-based therapies, an area that has attracted increasing attention as pharmaceutical companies search for new treatments for complex mental health conditions.
Analysts at BMO Capital Markets said the acquisition would provide Eli Lilly with a platform of rapid-acting psychedelic medicines while expanding its presence in treatment-resistant depression (TRD) and other difficult-to-treat psychiatric disorders. The brokerage maintained its "Outperform" rating on Lilly and a $1,300 price target, citing the long-term growth potential of psychedelic therapies as regulatory support continues to improve.
AtaiBeckley is developing innovative treatments for treatment-resistant depression and social anxiety disorder. Its leading drug candidate, BPL-003, is a fast-acting psychedelic nasal spray that has produced encouraging mid-stage clinical trial results and has received the U.S. Food and Drug Administration’s Breakthrough Therapy designation.
In addition to BPL-003, the company’s pipeline includes VLS-01 for treatment-resistant depression and EMP-01 for social anxiety disorder. Analysts believe these programs could provide Lilly with valuable late-stage assets and broaden its pipeline of psychiatric treatments.
The psychedelic medicine sector has gained momentum in recent years, driven by positive clinical data and the commercial success of Johnson & Johnson’s Spravato, an approved therapy for treatment-resistant depression. If completed, the acquisition would position Eli Lilly to capitalize on the growing market for innovative mental health treatments while reinforcing its long-term strategy in neuroscience and psychiatric drug development.
